Vesota 250 mg Solution for injection
PDF Leaflet Revision Date: 25 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women.
Dosage (summary)
500 mg at 1-month intervals; additional 500 mg 2 weeks after initial dose.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to fulvestrant
- Severe hepatic impairment
- Pregnancy
- Breastfeeding
Common side effects
- Injection site reactions
- Asthenia
- Nausea
- Increased hepatic enzymes
Counselling Points
- Use effective contraception during treatment and for 2 years after.
- Report any severe injection site reactions.
- Avoid alcohol due to ethanol content.
Serious warnings
- Hypersensitivity reactions
- Caution in hepatic impairment
- Caution in renal impairment
Important Disclaimer
The Vesota 250 mg Solution for injection professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
